Skip to content

The efficacy and safety of argatroban for venous catheter lock solution: prospective, open-label, randomized controlled trial

The efficacy and safety of argatroban for venous catheter lock solution: prospective, open-label, randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017105
Enrollment
Unknown
Registered
2018-07-12
Start date
2018-08-01
Completion date
Unknown
Last updated
2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal insufficiency

Interventions

Group 1:argatroban for lock solution
Group 2:Heparin for lock solution

Sponsors

Dept. of Nephrology,General Hospital of PLA, Beijing
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged older than 18 years male and female; 2. Clinical diagnosis of acute kidney injury/chronic renal failure, receiving hemodialysis treatment; 3. Use temporary or long-term central venous catheters as a blood pathway; 4. Hemodialysis frequency: 3 times/week, 4 hours/time; 5. Signing informed consent.

Exclusion criteria

Exclusion criteria: 1. Receive systemic anticoagulant therapy; 2. Heparin-induced thrombocytopenia or allergies; 3. argatroban allergy; 4. Apply long-term central venous catheters to infect or catheter dysfunction; 5. There is a systemic or local infection at the time of enrollment; 6. Patients with malignant tumors; 7. Pregnancy or breastfeeding; 8. Participating in another clinical researcher.

Design outcomes

Primary

MeasureTime frame
Thrombosis rate;Catheter infection rate;

Countries

China

Contacts

Public ContactXuefeng Sun

Dept. of Nephrology,General Hospital of PLA

xfssun@126.com+86 18811057304

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 16, 2026